Answers are grounded in this paper and cite their sources.
A group of multibacillary patients is clearly at high risk for relapse following 2-yr WHO-MDT. Relapse is largely confined to BL or LL patients with a high BI initially, and occurs long after the discontinuation of therapy. This important group of patients at risk for treatment failure presents several important issues: the need to identify those at risk and the operational requirements needed for their long term follow-up. Also, this group of patients might well benefit from an alternative antimicrobial regimen from the outset, as well as upon relapse.
No takes yet. Share an insight, caveat, or question.
GELBER et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: